TY - JOUR
T1 - Vaccine escape of piliated Streptococcus pneumoniae strains
AU - PICR study group
AU - Regev-Yochay, Gili
AU - Jaber, Hanaa
AU - Hamdan, Ayob
AU - Daana, Muhannad
AU - Nammouz, Hanan
AU - Thalji, Amin
AU - Jaar, Fuad
AU - Abdeen, Ziad
AU - Rubin, Carmit
AU - Huppert, Amit
AU - Raz, Meir
AU - Rahav, Galia
AU - Abullaish, Izzeldin
AU - Affiffi, Muhammed
AU - Amit, Yair
AU - Bassem, Yunes
AU - Cohen, Adi
AU - Dandis, Ibrahim
AU - ElHam-dany, Abedalla
AU - Hasselton, Samantha
AU - Husseini, Muhammed
AU - Kawather, Laduyeh
AU - Osher, Marian
AU - Rodity, Avraham
AU - Roizin, Hector
AU - Siag, Waeel
AU - Stern, Ora
AU - Yakirevitch, Luba
AU - Zecayra, Khairi
N1 - Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/5/27
Y1 - 2016/5/27
N2 - Introduction: Type1-pilus proteins were suggested as targets of future protein-based vaccines. Here we studied the effect of pneumococcal-conjugate vaccine (PCV7) implementation on the prevalence of piliated strains in a unique study setting which controls for typical confounders; the Palestinian-Israeli Collaborative Research (PICR). Methods: Annual cross-sectional surveys of pneumococcal carriage were performed during 2009-2011 among two closely related population that live under different health policies (a) Palestinian-Authority (PA) (n = 1773), where PCV7 was not yet introduced (b) East-Jerusalem (EJ) (n = 983) where PCV7 was rapidly implemented. Clinical data were collected, pneumococci identified and characterized and the presence of Type1-pilus genes was determined by rrgC PCR. Results: Following PCV7 implementation in EJ, overall carriage prevalence did not change (~30%), but VT7 strains decreased from 61.5% to 33.8%. While prevalence of non-piliated-VT7 isolates decreased from 37% to 10%, p < 0.001, the prevalence of piliated-VT7 strains persisted ~25%. Additionally, piliated non-VT13 strains emerged (1-15%, p < 0.001). These changes were not observed in PA. These dynamics were independent of the bacteria's resistance pattern. Conclusions: A differential effect of PCV7 was observed with a relative resistance of piliated strains to the vaccine. This suggests that Type1-pilus confers an intrinsic advantage for colonization and may be an attractive vaccine target.
AB - Introduction: Type1-pilus proteins were suggested as targets of future protein-based vaccines. Here we studied the effect of pneumococcal-conjugate vaccine (PCV7) implementation on the prevalence of piliated strains in a unique study setting which controls for typical confounders; the Palestinian-Israeli Collaborative Research (PICR). Methods: Annual cross-sectional surveys of pneumococcal carriage were performed during 2009-2011 among two closely related population that live under different health policies (a) Palestinian-Authority (PA) (n = 1773), where PCV7 was not yet introduced (b) East-Jerusalem (EJ) (n = 983) where PCV7 was rapidly implemented. Clinical data were collected, pneumococci identified and characterized and the presence of Type1-pilus genes was determined by rrgC PCR. Results: Following PCV7 implementation in EJ, overall carriage prevalence did not change (~30%), but VT7 strains decreased from 61.5% to 33.8%. While prevalence of non-piliated-VT7 isolates decreased from 37% to 10%, p < 0.001, the prevalence of piliated-VT7 strains persisted ~25%. Additionally, piliated non-VT13 strains emerged (1-15%, p < 0.001). These changes were not observed in PA. These dynamics were independent of the bacteria's resistance pattern. Conclusions: A differential effect of PCV7 was observed with a relative resistance of piliated strains to the vaccine. This suggests that Type1-pilus confers an intrinsic advantage for colonization and may be an attractive vaccine target.
KW - PCV7 effects
KW - Pilus type-1
KW - Pneumococcal vaccines
KW - Population-based study
UR - http://www.scopus.com/inward/record.url?scp=84964916979&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2016.04.064
DO - 10.1016/j.vaccine.2016.04.064
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 27133876
AN - SCOPUS:84964916979
SN - 0264-410X
VL - 34
SP - 2787
EP - 2792
JO - Vaccine
JF - Vaccine
IS - 25
ER -